scholarly journals Association of Mammographic Density Reduction with Hormone Therapy and Relapse in Asian Breast Cancer Patients: A Multivariate Survival Analysis

2021 ◽  
Author(s):  
Wei-Chung Shia ◽  
Hwa-Koon Wu ◽  
Li-Sheng Lin ◽  
Dar-Ren Chen
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Cancer Patients ◽  
Mammographic Density ◽  
Endocrine Resistance ◽  
Disease Free Survival ◽  
Mammographic Breast Density ◽  
Breast Cancer Patients ◽  
Free Survival

Abstract Purpose Currently, the ability to predict the development of resistance to hormone therapy (HT) in breast cancer patients is suboptimal, and attempts are ongoing to develop more specific prognostic markers for endocrine resistance. Several studies have shown that mammographic breast density is an important predictor of outcomes following adjuvant HT. This study aimed to evaluate HT-induced mammographic density (MD) reduction (MDR) and its association with relapse and metastasis in Taiwanese patients.MethodsIn this retrospective study conducted at the Changhua Christian Hospital, 1553 breast cancer patients were screened. Of these, 399 with luminal-like cancer who were first diagnosed between January 2011 and December 2017 and had received adjuvant HT (include treatment with tamoxifen, aromatase inhibitor or mixture) were enrolled. The mean follow-up period for all patients was 1847 days (median follow-up period was 1815 days). The MD was measured as a percentage using the automatic volumetric mammographic density estimation.ResultsWe found the MDR equally 20.8% which MD measured was before and after surgery and HT during 6 to 18 months was a significant cut-off threshold for good or pool diagnosis in breast cancer patients who receiving HT. By utilized the Cox proportion-hazards model analysis, the disease-free survival rate was significantly higher in MDR-positive patients (MDR > 20.8%) than in MDR-negative patients (MDR < 20.8%) (p = 0.048). Age, histologic grade, histologic stage, and lymph node metastasis showed a significant association with recurrence-free survival in all patients.ConclusionsOur results demonstrate the feasibility of using MDR to predict the preliminary outcomes of adjuvant HT in Asian breast cancer patients.

scholarly journals Overall survival and disease-free survival in breast cancer patients treated at the Oncology Centre in Bydgoszcz – analysis of more than six years of follow-up

2015 ◽  
Vol 4 ◽  
pp. 284-289 ◽  
Author(s):  
Tomasz Nowikiewicz ◽  
Magdalena Wiśniewska ◽  
Michał Wiśniewski ◽  
Marta Biedka ◽  
Iwona Głowacka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Oncology Centre ◽  
Disease Free

scholarly journals Elevated soluble Galectin-3 as a marker of chemotherapy efficacy in Breast cancer patients; a prospective study

2020 ◽  
Author(s):  
Arooj Shafiq ◽  
January Moore ◽  
Aliya Suleman ◽  
Sabeen Faiz ◽  
Omar Farooq ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Cancer Prognosis ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Galectin 3 ◽  
Chemotherapy Efficacy ◽  
Disease Free

ABSTRACTPurposeGalectin-3 (Gal-3) is a glycan-binding lectin with a debated role in cancer progression due to its various functions and patterns of expression. The current study investigates the relationship between breast cancer prognosis and secreted Gal-3.MethodsBreast cancer patients with first time cancer diagnosis and no prior treatment (n=88) were placed in either adjuvant or neoadjuvant setting based on their treatment modality. Stromal and plasma Gal-3 levels were measured in each patient at the time of diagnosis and then throughout treatment using immunohistochemistry (IHC) and ELISA respectively. Healthy women (>18 years of age, n=63) were used to establish baseline levels of plasma Gal-3. Patients were followed for 84 months for disease free survival analysis.ResultsEnhanced levels of plasma (adjuvant) and stromal (neo-adjuvant) Gal-3 were found to be markers of chemotherapy efficacy. The patients with chemotherapy induced increase in extracellular Gal-3 had longer disease-free interval and significantly lower rate of recurrence during 84-month follow-up compared to patients with unchanged or decreased secretion.ConclusionThe findings support the use of plasma Gal-3 as a marker for chemotherapy efficacy when no residual tumor is visible through imaging. Furthermore, stromal levels in any remaining tumors post chemotherapy can also be used to predict long term prognosis in patients.Key pointsIncreased Gal-3 secretion due to chemotherapy leads to better prognosis and longer disease-free survival.The analysis of soluble Gal-3 expression could be useful as a support tool in predicting treatment efficacy in patients with no visible tumor remaining for follow up through imaging.

scholarly journals Saving the Breast Saves the Lives of Breast Cancer Patients

2020 ◽  
Vol 2020 ◽  
pp. 1-8 ◽  
Author(s):  
Mohammad Esmaeil Akbari ◽  
Maryam Khayamzadeh ◽  
Hamid Reza Mirzaei ◽  
Afshin Moradi ◽  
Atieh Akbari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Breast Conserving Surgery ◽  
Breast Conserving Therapy ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Disease Free

Introduction. Surgery has been known as the procedure of choice for breast cancer management since 1700 years before Christ. Nowadays, breast-conserving surgery and mastectomy are performed in selected cases with specific clinical criteria. Here, we compare these two procedures for breast cancer patients with variable features in Cancer Research Center, Tehran, as a single institution experience. Methods. In this 25-year follow-up retrospective cohort study, we identified breast cancer patients who had undergone breast-conserving therapy or mastectomy. Disease-free survival and overall survival were evaluated using Kaplan–Meier survival analysis and the log-rank test between the two groups. A p value less than 0.05 was considered statistically significant. Results. A total of 3358 breast cancer patients, including 61% breast-conserving therapy and 39% mastectomy cases were identified, with a mean follow-up time of 94 months. The overall survival and disease-free survival of all cases were significantly better in breast-conserved patients, particularly in early-stage breast cancer with favorable clinical, pathological, and biological features. Ten-year disease-free survival and overall survival in breast-conserving therapy and mastectomy cases were 74%, 88% and 58%, 80%, respectively. Conclusion. Breast-conserving surgery and radiation therapy prove to be an appropriate treatment option for breast cancer patients in terms of overall survival and disease-free survival when indicated.

Neutrophil-lymphocyte index as prognostic factor for overall survival and disease-free survival in breast cancer patients

2020 ◽  
Vol 33 (4) ◽  
pp. 137-144
Author(s):  
Guillermo Peralta-Castillo ◽  
Antonio Maffuz-Aziz ◽  
Mariana Sierra-Murguía ◽  
Sergio Rodriguez-Cuevas
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Disease Free
Sign in / Sign up

Export Citation Format

Share Document